Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma-Reference-Cited by-同舟云学术

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

Published:2022-01-10 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Mørk Sofie Kirial¹,Kadivar Mohammad²,Bol Kalijn Fredrike¹,Draghi Arianna¹,Westergaard Marie Christine Wulff¹,Skadborg Signe Koggersbøl²,Overgaard Nana²,Sørensen Anders Bundgård³,Rasmussen Ida Svahn⁴,Andreasen Lars Vibe⁴,Yde Christina Westmose⁵,Trolle Thomas³,Garde Christian³,Friis-Nielsen Jens³,Nørgaard Nis⁶,Christensen Dennis⁴,Kringelum Jens Vindahl³,Donia Marco¹^ORCID,Hadrup Sine Reker²,Svane Inge Marie¹^ORCID

Affiliation:

1. National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

2. Department of Health Technology, Technical University of Denmark– DTU, HEALTH TECH, Lyngby, Denmark

3. Evaxion Biotech A/S, Denmark

4. Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark

5. Diagnostic Center Rigshospitalet, Genomic Medicine Rigshospitalet, Copenhagen, Denmark

6. Department of Urology, Copenhagen University Hospital, Herlev, Denmark

Funder

Innovation Fond Denmark, and the Danish Cancer Society

Publisher

Informa UK Limited

Subject